Ripretinib

Home/Tag: Ripretinib

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

By |2020-06-22T09:47:31-04:00June 22nd, 2020|Drug Treatment, News, Qinlock|

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|

Priority Review Granted for Ripretinib

Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).

By |2020-02-14T09:57:21-05:00February 14th, 2020|Drug Treatment, News|

Deciphera Releases Positive Trial Results for Ripretinib

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|
Go to Top